Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development

Immunovant, Inc.

Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.
Investors include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF, and Commodore Capital.
Net proceeds to accelerate IMVT-1402 development, including a proposed pivotal trial.
Existing cash plus offering proceeds expected to fund company into H2 2025.
Offering expected to close Oct 6, 2022; SVB Securities and Truist Securities are joint bookrunners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.